Virtual Screening and Molecular Docking: Discovering Novel METTL3 Inhibitors-Reference-Cited by-同舟云学术

Virtual Screening and Molecular Docking: Discovering Novel METTL3 Inhibitors

Published:2024-08-06 Issue: Volume: Page:
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Yang Junyi¹²,He Yanwen¹²^ORCID,Kang Youkun¹²,Shen Liteng³,Zhang Wen¹²,Yan Yumeng¹²,Li Xinyi¹²,Huang Wenhai¹²,Xu Xiangwei¹²^ORCID

Affiliation:

1. Affiliated Yongkang First People’s Hospital and School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, Zhejiang 311399, China

2. Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310013, China

3. Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China

Funder

National College Students Innovation and Entrepreneurship Training Program

Innovation and Entrepreneurship Training Program for College Students of Zhejiang Province

Science and Technological Innovation Project for College Students in Zhejiang Province

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.4c00216

Reference30 articles.

1. RMBase: a resource for decoding the landscape of RNA modifications from high-throughput sequencing data

2. N6-methyladenine modification in noncoding RNAs and its function in cancer

3. Small‐Molecule Inhibitors of METTL3, the Major Human Epitranscriptomic Writer

4. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO

5. ALKBH5-dependent m6A demethylation controls splicing and stability of long 3′-UTR mRNAs in male germ cells